[{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Alter Pharma group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pyridostigmine","moa":"AchE","graph1":"Immunology","graph2":"Approved","graph3":"Milla Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Milla Pharmaceuticals \/ Alter Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Milla Pharmaceuticals \/ Alter Pharma"},{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Milla Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Milla Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Milla Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Woodward Pharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sodium Acetate","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Milla Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Milla Pharmaceuticals \/ Woodward Pharma Services","highestDevelopmentStatusID":"12","companyTruncated":"Milla Pharmaceuticals \/ Woodward Pharma Services"},{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Acella Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pyridostigmine","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Milla Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Milla Pharmaceuticals \/ Milla Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Milla Pharmaceuticals \/ Milla Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Milla Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Sodium Acetate-generic Injection is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake.

                          Brand Name : Sodium Acetate-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 09, 2024

                          Lead Product(s) : Sodium Acetate

                          Therapeutic Area : Nephrology

                          Highest Development Status : Approved

                          Sponsor : Woodward Pharma Services

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Pyridostigmine Bromide, generic version of Mestinon, is a cholinesterase inhibitor small molecule drug administered orally as a syrup for myasthenia gravis.

                          Brand Name : Mestinon-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 11, 2023

                          Lead Product(s) : Pyridostigmine

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Recipient : Acella Pharmaceuticals

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Dexmedetomidine hydrochloride Injection is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting.

                          Brand Name : Precedex-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 09, 2023

                          Lead Product(s) : Dexmedetomidine Hydrochloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Abbreviated New Drug Application (ANDA) for a generic version of Mestinon (Pyridostigmine Bromide Syrup) 60 mg/5mL, is indicated for symptomatic treatment of myasthenia gravis.

                          Brand Name : Pyridostigmine Bromide-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 19, 2022

                          Lead Product(s) : Pyridostigmine

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Sponsor : Alter Pharma group

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank